11282-Lymphomas-Hodgkins-1519

Lymphomas

(SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy

  • Details

ClinicalTrials.gov ID: NCT01716806
Diagnosis Type: Hodgkins
USOR Number: 11282

  • Address

1105 Central Expressway, Suite 320
Allen, TX 75013
P: (469) 467-4392

Find a Clinical Trial

Search by practice name, trial titles, indicators and specific disease types.